Welcome to our dedicated page for Vaxart news (Ticker: VXRT), a resource for investors and traders seeking the latest updates and insights on Vaxart stock.
Vaxart Inc. (VXRT) is a clinical-stage biotechnology company pioneering oral tablet vaccines for infectious diseases. This page aggregates official announcements, financial disclosures, and scientific developments related to its recombinant vaccine platform and clinical pipeline.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes earnings reports, manufacturing updates, and peer-reviewed research findings – all essential for evaluating Vaxart's position in the competitive vaccine market.
Key content focuses on tablet vaccine efficacy data, FDA communications, intellectual property developments, and comparative analyses of mucosal immunization approaches. Bookmark this page to monitor Vaxart's progress in redefining vaccine administration through its temperature-stable oral delivery system.
Vaxart, Inc. (Nasdaq: VXRT) announced that all six proposals in its 2022 Proxy Statement were approved at the reconvened Annual Meeting of Stockholders on August 4, 2022. Proposal 2, which increases the authorized shares to 250 million, received 82% support, surpassing the required 50%. Proposals 3 and 4, amendments to the Equity Incentive Plan and the Employee Stock Purchase Plan, were contingent on the passage of Proposal 2. This strong backing reflects stockholder confidence in Vaxart's oral vaccine programs.
Vaxart, Inc. (NASDAQ: VXRT) announced it will report its Q2 2022 financial results on August 8, 2022, after market close. A conference call hosted by senior management will begin at 4:30 p.m. ET to provide a business update and discuss financials. Vaxart is a clinical-stage biotech company focused on developing oral recombinant vaccines for various diseases, including coronavirus and norovirus. The company utilizes a unique tablet delivery system, aiming to enhance vaccine accessibility and safety.
Vaxart, Inc. (Nasdaq: VXRT) announced its request for stockholders to vote on Proxy Proposal #2, which aims to increase authorized shares to 250 million. As of now, 49.1% of shares have voted in favor, needing an additional 0.9% for approval by the August 3, 2022, deadline. Notably, over 80% of the votes cast so far support the proposal, with backing from leading proxy advisory firms ISS and Glass Lewis. CEO Andrei Floroiu emphasized the proposal's importance for business growth and competitive positioning.
Vaxart's recent phase 1 clinical trial data reveals its Spike/Nucleocapsid (S+N) oral tablet COVID-19 vaccine induces long-lasting mucosal IgA antibody responses, with effects lasting up to one year. These IgA antibodies exhibited greater neutralizing activity than those from convalescent samples. The study involved 35 healthy participants and confirmed the vaccine's tolerability and immunogenicity. Vaxart aims to leverage these findings for future vaccine candidate development as part of ongoing efforts to address emerging SARS-CoV-2 variants.
Vaxart, Inc. (Nasdaq: VXRT) announced that its Chief Scientific Officer, Dr. Sean Tucker, and Senior Scientist, Dr. Rebecca Flitter, will present data on its COVID-19 oral tablet vaccine at the International Congress of Mucosal Immunology 2022, scheduled for July 16-20 in Seattle. On July 18, Dr. Tucker will discuss oral vaccination's ability to induce pan-coronavirus nasal IgA responses, while Dr. Flitter will present findings on mucosal rAd5 immunization against SARS-CoV-2, showcasing its effectiveness in non-human primates.
Vaxart, Inc. (Nasdaq: VXRT) is urging stockholders to vote on Proxy Proposal #2 by July 5, 2022, which seeks to increase authorized shares to 250 million. This proposal is backed by ISS and Glass Lewis, indicating strong support. Currently, 76% of present voting shares favor the proposal, but it requires more than 50% of all outstanding shares to pass. CEO Andrei Floroiu emphasizes that approval would enhance capital-raising flexibility, aiding Vaxart's promising pipeline and competitive position. Stockholders can vote online, by phone, or via mail.
Vaxart, Inc. (Nasdaq: VXRT) has entered an agreement with hVIVO Services Limited to develop a human challenge model based on the Omicron variant of SARS-CoV-2. This initiative aims to support a Phase II Human Challenge Trial of Vaxart's oral COVID-19 vaccine pill candidate. Vaxart is pioneering the use of an Omicron-specific challenge study, making it the first company to do so. The successful execution of the challenge study is expected to start in 2023, contingent upon regulatory approvals.
Vaxart, Inc. (Nasdaq: VXRT) announced a Q&A webcast with investors and analysts on June 22, 2022, at 1:00 p.m. ET, featuring CEO Andrei Floroiu, SVP Dr. Sean Tucker, and CMO Dr. James Cummings. They will discuss the company's oral vaccine programs and answer submitted questions. The event will be available for replay two hours after its conclusion on Vaxart's website. Additionally, Vaxart’s 2022 annual meeting has been rescheduled to July 6, 2022, at 12:30 p.m. ET, encouraging stockholders to vote by July 5, 2022.
Vaxart, Inc. (Nasdaq: VXRT) has announced the adjournment of its 2022 annual meeting of stockholders to July 6, 2022, at 9:30 a.m. PT. Stockholders of record as of April 11, 2022, are encouraged to vote by July 5, 2022, at 11:59 p.m. ET. Approximately 58.22% of shares were voted, with key proposals mostly approved, except for an amendment to increase authorized shares. This amendment's failure may hinder Vaxart's abilities in raising capital and strategic planning. The meeting will be accessible via live webcast.
Vaxart (NASDAQ: VXRT) reported promising preliminary preclinical data for its COVID-19 vaccine candidates targeting the SARS-CoV-2 variants. Both the Wuhan and Omicron specific vaccines demonstrated protective effects in hamsters against the Omicron BA.1 variant, with the Omicron candidate showing superior antibody response. Weight loss and viral load were reduced in vaccinated animals compared to unvaccinated ones. Vaxart continues to leverage evolving pandemic data for vaccine development strategies, advancing toward clinical trials.
FAQ
What is the current stock price of Vaxart (VXRT)?
What is the market cap of Vaxart (VXRT)?
